# Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

> **NCT05480046** · — · COMPLETED · sponsor: **Rovi Pharmaceuticals Laboratories** · enrollment: 275 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone ISM

## Key facts

- **NCT ID:** NCT05480046
- **Lead sponsor:** Rovi Pharmaceuticals Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-18
- **Primary completion:** 2025-03-13
- **Final completion:** 2025-03-13
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05480046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05480046, "Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05480046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*